An Open-label Phase 2 Study of Olaptesed Pegol (NOX-A12) Combined With Pembrolizumab and Nanoliposomal Irinotecan/5-FU/Leucovorin or Gemcitabine/Nab-paclitaxel in Microsatellite-stable Metastatic Pancreatic Cancer Patients
Latest Information Update: 13 Jun 2024
At a glance
- Drugs Fluorouracil (Primary) ; Folinic acid (Primary) ; Gemcitabine (Primary) ; Irinotecan (Primary) ; Olaptesed pegol (Primary) ; Paclitaxel (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms OPTIMUS
- Sponsors TME Pharma
- 10 Jun 2024 Planned End Date changed from 1 Oct 2027 to 1 Oct 2028.
- 10 Jun 2024 Planned primary completion date changed from 1 Oct 2026 to 1 Oct 2027.
- 10 Jun 2024 Planned initiation date changed from 1 Jun 2024 to 1 Jun 2025.